You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMetamizole
Accession NumberDB04817
TypeSmall Molecule
GroupsWithdrawn
DescriptionMetamizole, formerly marketed as Dimethone tablets and injection, Protemp oral liquid, and other drug products, was associated with potentially fatal agranulocytosis. Approvals of the NDA's for dipyrone drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977 (42 FR 30893)). Withdrawn from the Canadian market in 1963.
Structure
Thumb
Synonyms
Dipyrone
External Identifiers Not Available
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlgocalminNot Available
AlgozoneNot Available
AnalginNot Available
DimethoneNot Available
DipironaNot Available
Neo-MelubrinaNot Available
NovalginNot Available
OptalginNot Available
ProtempNot Available
PyralginNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Metamizole sodium
68-89-3
Thumb
  • InChI Key: DJGAAPFSPWAYTJ-UHFFFAOYSA-M
  • Monoisotopic Mass: 333.07592138
  • Average Mass: 333.339
DBSALT000332
Categories
UNII934T64RMNJ
CAS number50567-35-6
WeightAverage: 333.339
Monoisotopic: 333.07592138
Chemical FormulaC13H16N3NaO4S
InChI KeyInChIKey=DJGAAPFSPWAYTJ-UHFFFAOYSA-M
InChI
InChI=1S/C13H17N3O4S.Na/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11;/h4-8H,9H2,1-3H3,(H,18,19,20);/q;+1/p-1
IUPAC Name
sodium [(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)(methyl)amino]methanesulfonate
SMILES
[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassAzoles
Sub ClassPyrazoles
Direct ParentPhenylpyrazoles
Alternative Parents
Substituents
  • Phenylpyrazole
  • Dialkylarylamine
  • Benzenoid
  • Pyrazolinone
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Vinylogous amide
  • Alkanesulfonic acid
  • Sulfonyl
  • Sulfonic acid derivative
  • Sulfonic acid
  • Tertiary amine
  • Lactam
  • Azacycle
  • Hydrocarbon derivative
  • Organic alkali metal salt
  • Organic sodium salt
  • Organic salt
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Organic zwitterion
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors
Pharmacology
IndicationUsed in the past as a powerful painkiller and fever reducer.
PharmacodynamicsDipyrone is a non-steroidal anti-inflammatory drug (NSAID), commonly used in the past as a powerful painkiller and fever reducer.
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7868
Blood Brain Barrier+0.8896
Caco-2 permeable-0.5869
P-glycoprotein substrateNon-substrate0.8148
P-glycoprotein inhibitor INon-inhibitor0.828
P-glycoprotein inhibitor IINon-inhibitor0.8107
Renal organic cation transporterNon-inhibitor0.921
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.7959
CYP450 3A4 substrateSubstrate0.6035
CYP450 1A2 substrateNon-inhibitor0.7153
CYP450 2C9 inhibitorNon-inhibitor0.7064
CYP450 2D6 inhibitorNon-inhibitor0.8562
CYP450 2C19 inhibitorNon-inhibitor0.6768
CYP450 3A4 inhibitorNon-inhibitor0.9297
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8506
Ames testAMES toxic0.7763
CarcinogenicityCarcinogens 0.8197
BiodegradationReady biodegradable0.7192
Rat acute toxicity2.6224 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8411
hERG inhibition (predictor II)Non-inhibitor0.6724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility5.8 mg/mLALOGPS
logP1.07ALOGPS
logP-0.82ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)-1.2ChemAxon
pKa (Strongest Basic)-0.44ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area83.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.92 m3·mol-1ChemAxon
Polarizability31.11 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesN02BB02N02BB72N02BB52
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabMetamizole may increase the anticoagulant activities of Abciximab.
AcebutololMetamizole may decrease the antihypertensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Aceclofenac.
AcenocoumarolMetamizole may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Metamizole.
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Metamizole.
AldesleukinThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldesleukin.
AlemtuzumabThe risk or severity of adverse effects can be increased when Metamizole is combined with Alemtuzumab.
Alendronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.
AliskirenMetamizole may decrease the antihypertensive activities of Aliskiren.
AlprenololMetamizole may decrease the antihypertensive activities of Alprenolol.
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Metamizole.
AltretamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Altretamine.
AmikacinMetamizole may decrease the excretion rate of Amikacin which could result in a lower serum level and potentially a reduction in efficacy.
AmilorideMetamizole may decrease the antihypertensive activities of Amiloride.
AmsacrineThe risk or severity of adverse effects can be increased when Metamizole is combined with Amsacrine.
AncrodMetamizole may increase the anticoagulant activities of Ancrod.
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Metamizole.
Antithrombin III humanMetamizole may increase the anticoagulant activities of Antithrombin III human.
ApixabanMetamizole may increase the anticoagulant activities of Apixaban.
ApremilastThe risk or severity of adverse effects can be increased when Metamizole is combined with Apremilast.
ArdeparinMetamizole may increase the anticoagulant activities of Ardeparin.
ArgatrobanMetamizole may increase the anticoagulant activities of Argatroban.
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.
ArotinololMetamizole may decrease the antihypertensive activities of Arotinolol.
Arsenic trioxideThe risk or severity of adverse effects can be increased when Metamizole is combined with Arsenic trioxide.
AtenololMetamizole may decrease the antihypertensive activities of Atenolol.
AzacitidineThe risk or severity of adverse effects can be increased when Metamizole is combined with Azacitidine.
AzapropazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.
BalsalazideMetamizole may increase the nephrotoxic activities of Balsalazide.
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Metamizole.
BecaplerminMetamizole may increase the anticoagulant activities of Becaplermin.
BefunololMetamizole may decrease the antihypertensive activities of Befunolol.
BelinostatThe risk or severity of adverse effects can be increased when Metamizole is combined with Belinostat.
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Metamizole.
BendamustineThe risk or severity of adverse effects can be increased when Metamizole is combined with Bendamustine.
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole.
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Metamizole.
BetaxololMetamizole may decrease the antihypertensive activities of Betaxolol.
BevacizumabThe risk or severity of adverse effects can be increased when Metamizole is combined with Bevacizumab.
BevantololMetamizole may decrease the antihypertensive activities of Bevantolol.
BexaroteneThe risk or severity of adverse effects can be increased when Metamizole is combined with Bexarotene.
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Metamizole.
BisoprololMetamizole may decrease the antihypertensive activities of Bisoprolol.
BivalirudinMetamizole may increase the anticoagulant activities of Bivalirudin.
BlinatumomabThe risk or severity of adverse effects can be increased when Metamizole is combined with Blinatumomab.
BopindololMetamizole may decrease the antihypertensive activities of Bopindolol.
BortezomibThe risk or severity of adverse effects can be increased when Metamizole is combined with Bortezomib.
BosutinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Bosutinib.
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Metamizole.
BufuralolMetamizole may decrease the antihypertensive activities of Bufuralol.
BumetanideMetamizole may decrease the diuretic activities of Bumetanide.
BupranololMetamizole may decrease the antihypertensive activities of Bupranolol.
BusulfanThe risk or severity of adverse effects can be increased when Metamizole is combined with Busulfan.
CabazitaxelThe risk or severity of adverse effects can be increased when Metamizole is combined with Cabazitaxel.
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.
CandoxatrilThe risk or severity of adverse effects can be increased when Candoxatril is combined with Metamizole.
CapecitabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Capecitabine.
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Metamizole.
CarbamazepineThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbamazepine.
CarboplatinThe risk or severity of adverse effects can be increased when Metamizole is combined with Carboplatin.
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole.
CarfilzomibThe risk or severity of adverse effects can be increased when Metamizole is combined with Carfilzomib.
CarmustineThe risk or severity of adverse effects can be increased when Metamizole is combined with Carmustine.
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Metamizole.
CarteololMetamizole may decrease the antihypertensive activities of Carteolol.
CarvedilolMetamizole may decrease the antihypertensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Metamizole.
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Metamizole.
CeliprololMetamizole may decrease the antihypertensive activities of Celiprolol.
CertoparinMetamizole may increase the anticoagulant activities of Certoparin.
ChlorambucilThe risk or severity of adverse effects can be increased when Metamizole is combined with Chlorambucil.
ChloramphenicolThe risk or severity of adverse effects can be increased when Metamizole is combined with Chloramphenicol.
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Metamizole.
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Metamizole.
CholestyramineCholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Metamizole.
CisplatinThe risk or severity of adverse effects can be increased when Metamizole is combined with Cisplatin.
Citric AcidMetamizole may increase the anticoagulant activities of Citric Acid.
CladribineThe risk or severity of adverse effects can be increased when Metamizole is combined with Cladribine.
ClodronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Clodronate.
ClofarabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Clofarabine.
ClonixinThe risk or severity of adverse effects can be increased when Metamizole is combined with Clonixin.
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Metamizole.
ColesevelamColesevelam can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.
CyclophosphamideThe risk or severity of adverse effects can be increased when Metamizole is combined with Cyclophosphamide.
CyclosporineMetamizole may increase the nephrotoxic activities of Cyclosporine.
CytarabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Cytarabine.
D-LimoneneThe risk or severity of adverse effects can be increased when Metamizole is combined with D-Limonene.
Dabigatran etexilateMetamizole may increase the anticoagulant activities of Dabigatran etexilate.
DacarbazineThe risk or severity of adverse effects can be increased when Metamizole is combined with Dacarbazine.
DactinomycinThe risk or severity of adverse effects can be increased when Metamizole is combined with Dactinomycin.
DalteparinMetamizole may increase the anticoagulant activities of Dalteparin.
DanaparoidMetamizole may increase the anticoagulant activities of Danaparoid.
DasatinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Dasatinib.
DaunorubicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Daunorubicin.
DecitabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Decitabine.
DeferasiroxThe risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox.
DesirudinMetamizole may increase the anticoagulant activities of Desirudin.
DesmopressinThe risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metamizole.
DexrazoxaneThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexrazoxane.
DextranMetamizole may increase the anticoagulant activities of Dextran.
Dextran 40Metamizole may increase the anticoagulant activities of Dextran 40.
Dextran 70Metamizole may increase the anticoagulant activities of Dextran 70.
Dextran 75Metamizole may increase the anticoagulant activities of Dextran 75.
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole.
DicoumarolMetamizole may increase the anticoagulant activities of Dicoumarol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Metamizole.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Metamizole.
DihydrostreptomycinMetamizole may decrease the excretion rate of Dihydrostreptomycin which could result in a lower serum level and potentially a reduction in efficacy.
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Metamizole.
DinutuximabThe risk or severity of adverse effects can be increased when Metamizole is combined with Dinutuximab.
DocetaxelThe risk or severity of adverse effects can be increased when Metamizole is combined with Docetaxel.
DoxorubicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Doxorubicin.
DrospirenoneMetamizole may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Droxicam.
Edetic AcidMetamizole may increase the anticoagulant activities of Edetic Acid.
EdoxabanMetamizole may increase the anticoagulant activities of Edoxaban.
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Metamizole.
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Metamizole.
EnoxaparinMetamizole may increase the anticoagulant activities of Enoxaparin.
EpirizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Epirizole.
EpirubicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Epirubicin.
EplerenoneMetamizole may decrease the antihypertensive activities of Eplerenone.
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.
EribulinThe risk or severity of adverse effects can be increased when Metamizole is combined with Eribulin.
EsmololMetamizole may decrease the antihypertensive activities of Esmolol.
Etacrynic acidMetamizole may decrease the diuretic activities of Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Metamizole.
Ethyl biscoumacetateMetamizole may increase the anticoagulant activities of Ethyl biscoumacetate.
Etidronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid.
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Metamizole.
EtofenamateThe risk or severity of adverse effects can be increased when Metamizole is combined with Etofenamate.
EtoposideThe risk or severity of adverse effects can be increased when Metamizole is combined with Etoposide.
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Metamizole.
Evening primrose oilThe risk or severity of adverse effects can be increased when Metamizole is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Metamizole is combined with Everolimus.
exisulindThe risk or severity of adverse effects can be increased when Metamizole is combined with exisulind.
FenbufenThe risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen.
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Metamizole.
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metamizole.
FloxuridineThe risk or severity of adverse effects can be increased when Metamizole is combined with Floxuridine.
FlucytosineThe risk or severity of adverse effects can be increased when Metamizole is combined with Flucytosine.
FludarabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Fludarabine.
FlunixinThe risk or severity of adverse effects can be increased when Metamizole is combined with Flunixin.
FluorouracilThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluorouracil.
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Metamizole.
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole.
Fondaparinux sodiumMetamizole may increase the anticoagulant activities of Fondaparinux sodium.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Metamizole.
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Metamizole.
FramycetinMetamizole may decrease the excretion rate of Framycetin which could result in a lower serum level and potentially a reduction in efficacy.
FurosemideMetamizole may decrease the diuretic activities of Furosemide.
GemcitabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Gemcitabine.
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Metamizole.
Gemtuzumab ozogamicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Gemtuzumab ozogamicin.
GentamicinMetamizole may decrease the excretion rate of Gentamicin which could result in a lower serum level and potentially a reduction in efficacy.
HaloperidolThe risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.
HeparinMetamizole may increase the anticoagulant activities of Heparin.
HirulogMetamizole may increase the anticoagulant activities of Hirulog.
HMPL-004The risk or severity of adverse effects can be increased when Metamizole is combined with HMPL-004.
HydralazineMetamizole may decrease the antihypertensive activities of Hydralazine.
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Metamizole.
HydroxyureaThe risk or severity of adverse effects can be increased when Metamizole is combined with Hydroxyurea.
Hygromycin BMetamizole may decrease the excretion rate of Hygromycin B which could result in a lower serum level and potentially a reduction in efficacy.
IbandronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibrutinib.
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Metamizole.
IbuproxamThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibuproxam.
IcatibantThe risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant.
IdarubicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Idarubicin.
IfosfamideThe risk or severity of adverse effects can be increased when Metamizole is combined with Ifosfamide.
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.
ImatinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Imatinib.
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.
IndenololMetamizole may decrease the antihypertensive activities of Indenolol.
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Metamizole.
IndoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Indoprofen.
Interferon alfa-n3The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfa-n3.
Interferon alfacon-1The risk or severity of adverse effects can be increased when Metamizole is combined with Interferon alfacon-1.
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.
IrinotecanThe risk or severity of adverse effects can be increased when Metamizole is combined with Irinotecan.
IsoxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Isoxicam.
IxabepiloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Ixabepilone.
KanamycinMetamizole may decrease the excretion rate of Kanamycin which could result in a lower serum level and potentially a reduction in efficacy.
KebuzoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Kebuzone.
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Metamizole.
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole.
L-PhenylalanineThe risk or severity of adverse effects can be increased when Metamizole is combined with L-Phenylalanine.
LabetalolMetamizole may decrease the antihypertensive activities of Labetalol.
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Metamizole.
LenalidomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Lenalidomide.
LepirudinMetamizole may increase the anticoagulant activities of Lepirudin.
LevobunololMetamizole may decrease the antihypertensive activities of Levobunolol.
LinezolidThe risk or severity of adverse effects can be increased when Metamizole is combined with Linezolid.
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Metamizole.
LithiumThe serum concentration of Lithium can be increased when it is combined with Metamizole.
LomustineThe risk or severity of adverse effects can be increased when Metamizole is combined with Lomustine.
LornoxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.
LoxoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Loxoprofen.
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Metamizole.
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Metamizole.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Metamizole.
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole.
MechlorethamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Mechlorethamine.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Metamizole.
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Metamizole.
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Metamizole.
MelphalanThe risk or severity of adverse effects can be increased when Metamizole is combined with Melphalan.
MercaptopurineThe risk or severity of adverse effects can be increased when Metamizole is combined with Mercaptopurine.
MesalazineMetamizole may increase the nephrotoxic activities of Mesalazine.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Metamizole.
MethimazoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Methimazole.
MethotrexateThe risk or severity of adverse effects can be increased when Metamizole is combined with Methotrexate.
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.
MetipranololMetamizole may decrease the antihypertensive activities of Metipranolol.
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.
MetoprololMetamizole may decrease the antihypertensive activities of Metoprolol.
MetrizamideMetamizole may decrease the excretion rate of Metrizamide which could result in a lower serum level and potentially a reduction in efficacy.
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Metamizole.
MitomycinThe risk or severity of adverse effects can be increased when Metamizole is combined with Mitomycin.
MitoxantroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Mitoxantrone.
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Metamizole.
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Metamizole.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Metamizole.
NadololMetamizole may decrease the antihypertensive activities of Nadolol.
NadroparinMetamizole may increase the anticoagulant activities of Nadroparin.
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Metamizole.
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Metamizole.
NCX 4016The risk or severity of adverse effects can be increased when Metamizole is combined with NCX 4016.
NelarabineThe risk or severity of adverse effects can be increased when Metamizole is combined with Nelarabine.
NeomycinMetamizole may decrease the excretion rate of Neomycin which could result in a lower serum level and potentially a reduction in efficacy.
NepafenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Nepafenac.
NetilmicinMetamizole may decrease the excretion rate of Netilmicin which could result in a lower serum level and potentially a reduction in efficacy.
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Metamizole.
NilotinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Nilotinib.
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Metamizole.
NintedanibThe serum concentration of Nintedanib can be decreased when it is combined with Metamizole.
ObinutuzumabThe risk or severity of adverse effects can be increased when Metamizole is combined with Obinutuzumab.
OlaparibThe risk or severity of adverse effects can be increased when Metamizole is combined with Olaparib.
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metamizole.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.
OlsalazineMetamizole may increase the nephrotoxic activities of Olsalazine.
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Metamizole.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Metamizole is combined with Omacetaxine mepesuccinate.
OmapatrilatThe risk or severity of adverse effects can be increased when Omapatrilat is combined with Metamizole.
OrgoteinThe risk or severity of adverse effects can be increased when Metamizole is combined with Orgotein.
OtamixabanMetamizole may increase the anticoagulant activities of Otamixaban.
OxaliplatinThe risk or severity of adverse effects can be increased when Metamizole is combined with Oxaliplatin.
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Metamizole.
OxprenololMetamizole may decrease the antihypertensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.
PaclitaxelThe risk or severity of adverse effects can be increased when Metamizole is combined with Paclitaxel.
PalbociclibThe risk or severity of adverse effects can be increased when Metamizole is combined with Palbociclib.
PamidronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.
ParecoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Parecoxib.
ParomomycinMetamizole may decrease the excretion rate of Paromomycin which could result in a lower serum level and potentially a reduction in efficacy.
Peginterferon alfa-2aThe risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2a.
Peginterferon alfa-2bThe risk or severity of adverse effects can be increased when Metamizole is combined with Peginterferon alfa-2b.
PemetrexedThe risk or severity of adverse effects can be increased when Metamizole is combined with Pemetrexed.
PenbutololMetamizole may decrease the antihypertensive activities of Penbutolol.
Pentosan PolysulfateMetamizole may increase the anticoagulant activities of Pentosan Polysulfate.
PentostatinThe risk or severity of adverse effects can be increased when Metamizole is combined with Pentostatin.
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Metamizole.
PhenindioneMetamizole may increase the anticoagulant activities of Phenindione.
PhenprocoumonMetamizole may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Metamizole.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.
PindololMetamizole may decrease the antihypertensive activities of Pindolol.
PiretanideMetamizole may decrease the diuretic activities of Piretanide.
PirfenidoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Metamizole.
PlicamycinMetamizole may decrease the excretion rate of Plicamycin which could result in a lower serum level and potentially a reduction in efficacy.
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Metamizole.
PomalidomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Pomalidomide.
PonatinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Ponatinib.
PractololMetamizole may decrease the antihypertensive activities of Practolol.
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Metamizole.
ProbenecidThe serum concentration of Metamizole can be increased when it is combined with Probenecid.
ProcarbazineThe risk or severity of adverse effects can be increased when Metamizole is combined with Procarbazine.
PropacetamolThe risk or severity of adverse effects can be increased when Metamizole is combined with Propacetamol.
PropranololMetamizole may decrease the antihypertensive activities of Propranolol.
PropylthiouracilThe risk or severity of adverse effects can be increased when Metamizole is combined with Propylthiouracil.
Prostaglandin D2The therapeutic efficacy of Prostaglandin D2 can be decreased when used in combination with Metamizole.
Protein CMetamizole may increase the anticoagulant activities of Protein C.
ProtocatechualdehydeMetamizole may increase the anticoagulant activities of Protocatechualdehyde.
PTC299The risk or severity of adverse effects can be increased when Metamizole is combined with PTC299.
PuromycinMetamizole may decrease the excretion rate of Puromycin which could result in a lower serum level and potentially a reduction in efficacy.
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Metamizole.
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Metamizole.
RaltitrexedThe risk or severity of adverse effects can be increased when Metamizole is combined with Raltitrexed.
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metamizole.
RescinnamineThe risk or severity of adverse effects can be increased when Rescinnamine is combined with Metamizole.
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Metamizole.
ReviparinMetamizole may increase the anticoagulant activities of Reviparin.
RibostamycinMetamizole may decrease the excretion rate of Ribostamycin which could result in a lower serum level and potentially a reduction in efficacy.
RisedronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.
RituximabThe risk or severity of adverse effects can be increased when Metamizole is combined with Rituximab.
RivaroxabanMetamizole may increase the anticoagulant activities of Rivaroxaban.
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Metamizole.
RuxolitinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Ruxolitinib.
SalicylamideThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Metamizole.
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Metamizole.
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Metamizole.
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Metamizole.
SeratrodastThe risk or severity of adverse effects can be increased when Metamizole is combined with Seratrodast.
SirolimusThe risk or severity of adverse effects can be increased when Metamizole is combined with Sirolimus.
SorafenibThe risk or severity of adverse effects can be increased when Metamizole is combined with Sorafenib.
SotalolMetamizole may decrease the antihypertensive activities of Sotalol.
SpectinomycinMetamizole may decrease the excretion rate of Spectinomycin which could result in a lower serum level and potentially a reduction in efficacy.
SpiraprilThe risk or severity of adverse effects can be increased when Spirapril is combined with Metamizole.
SpironolactoneMetamizole may decrease the antihypertensive activities of Spironolactone.
SRT501The risk or severity of adverse effects can be increased when Metamizole is combined with SRT501.
StreptomycinMetamizole may decrease the excretion rate of Streptomycin which could result in a lower serum level and potentially a reduction in efficacy.
StreptozocinThe risk or severity of adverse effects can be increased when Metamizole is combined with Streptozocin.
SulfasalazineMetamizole may increase the nephrotoxic activities of Sulfasalazine.
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Metamizole.
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Metamizole.
SulodexideMetamizole may increase the anticoagulant activities of Sulodexide.
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Metamizole.
TacrolimusMetamizole may increase the nephrotoxic activities of Tacrolimus.
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Metamizole.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Metamizole.
Technetium Tc-99m MedronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Technetium Tc-99m Medronate.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Metamizole is combined with Tedizolid Phosphate.
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.
TemocaprilThe risk or severity of adverse effects can be increased when Temocapril is combined with Metamizole.
TemozolomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Temozolomide.
TemsirolimusThe risk or severity of adverse effects can be increased when Metamizole is combined with Temsirolimus.
TeniposideThe risk or severity of adverse effects can be increased when Metamizole is combined with Teniposide.
TenofovirThe risk or severity of adverse effects can be increased when Metamizole is combined with Tenofovir.
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Metamizole.
TepoxalinThe risk or severity of adverse effects can be increased when Metamizole is combined with Tepoxalin.
TeriflunomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Teriflunomide.
ThalidomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Thalidomide.
ThiotepaThe risk or severity of adverse effects can be increased when Metamizole is combined with Thiotepa.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Metamizole.
TiludronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronate.
TimololMetamizole may decrease the antihypertensive activities of Timolol.
TioguanineThe risk or severity of adverse effects can be increased when Metamizole is combined with Tioguanine.
TobramycinMetamizole may decrease the excretion rate of Tobramycin which could result in a lower serum level and potentially a reduction in efficacy.
TofacitinibThe risk or severity of adverse effects can be increased when Metamizole is combined with Tofacitinib.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Metamizole.
TopotecanThe risk or severity of adverse effects can be increased when Metamizole is combined with Topotecan.
TorasemideMetamizole may decrease the diuretic activities of Torasemide.
TositumomabThe risk or severity of adverse effects can be increased when Metamizole is combined with Tositumomab.
TrabectedinThe risk or severity of adverse effects can be increased when Metamizole is combined with Trabectedin.
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Metamizole.
TranilastThe risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.
Trastuzumab emtansineThe risk or severity of adverse effects can be increased when Metamizole is combined with Trastuzumab emtansine.
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.
TriamtereneMetamizole may decrease the antihypertensive activities of Triamterene.
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Metamizole.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Metamizole.
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Metamizole.
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Metamizole.
VinblastineThe risk or severity of adverse effects can be increased when Metamizole is combined with Vinblastine.
VindesineThe risk or severity of adverse effects can be increased when Metamizole is combined with Vindesine.
VinorelbineThe risk or severity of adverse effects can be increased when Metamizole is combined with Vinorelbine.
VorinostatThe risk or severity of adverse effects can be increased when Metamizole is combined with Vorinostat.
WarfarinMetamizole may increase the anticoagulant activities of Warfarin.
XimelagatranMetamizole may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen.
ZidovudineThe risk or severity of adverse effects can be increased when Metamizole is combined with Zidovudine.
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Metamizole.
Zoledronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Zoledronic acid.
ZomepiracThe risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Prostaglandin-endoperoxide synthase activity
Specific Function:
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gastric epithelial cells, it is a key step in the generation of prostaglandins, such as prostaglandin E2 (PGE2), which plays an important role in cytoprotection. In platelets, it is involved in the gener...
Gene Name:
PTGS1
Uniprot ID:
P23219
Molecular Weight:
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on September 11, 2007 14:09 / Updated on August 17, 2016 12:24